Elsevier

Advanced Drug Delivery Reviews

Volume 21, Issue 2, 16 September 1996, Pages 117-133
Advanced Drug Delivery Reviews

Therapeutic opportunities for targeted liposomal drug delivery

https://doi.org/10.1016/S0169-409X(96)00402-4Get rights and content

Abstract

One way to increase the therapeutic index of drugs such as anticancer drugs, which have low therapeutic indices would be by specifically targeting the drugs to the diseased cells. This can be accomplished by associating the drugs with liposomes and coupling a targeting antibody or ligand to the liposome surface. A variety of coupling methods can be used to attach antibodies or ligands to the liposomes, and, to date, the best targeting results have been obtained when the targeting moiety is attached at the terminus of a hydrophillic polymer such as polyethylene glycol (PEG). Targeted liposomes have been demonstrated to have specific binding and increased cytotoxicity to cells in vitro compared to non-targeted liposomes. The best therapeutic results in vivo have been obtained to date when the liposomes are targeted to cells easily accessible within the vasculature, or to micrometastatic cells. Treatment of more advanced solid tumours with targeted liposomes presents a challenge to overcome the ‘binding site barrier’ at the tumour surface. Evidence is accumulating that targeting to internalizing receptors is more successful than targeting to non-internalizing receptors.

References (100)

  • A.L. Klibanov et al.

    Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

    FEBS Lett.

    (1990)
  • J. Senior et al.

    Influence of surface hydrophobicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly (ethylene glycol)-coated vesicles

    Biochim. Biophys. Acta

    (1991)
  • T.M. Allen et al.

    Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

    Biochim. Biophys. Acta

    (1991)
  • T.M. Allen

    The use of glycolipids and hydrophillic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system

    Adv. Drug Del. Rev.

    (1994)
  • M.J. Parr et al.

    Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles

    Biochim. Biophys. Acta

    (1994)
  • T.M. Allen et al.

    Pharmacokinetics of Stealth versus conventional liposomes: effect of dose

    Biochim. Biophys. Acta

    (1991)
  • C.B. Hansen et al.

    Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures

    Biochim. Biophys. Acta

    (1995)
  • A. Mori et al.

    Influence of the steric barrier of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo

    FEBS Lett.

    (1991)
  • A.L. Klibanov et al.

    Activity of amphipathic poly(ethyleneglycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target

    Biochim. Biophys. Acta

    (1991)
  • F.J. Martin et al.

    Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting

    J. Biol. Chem.

    (1982)
  • H. Loughrey et al.

    A non-covalent method of attaching antibodies to liposomes

    Biochim. Biophys. Acta

    (1987)
  • A.A. Bogdanov et al.

    Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydorosulfosuccinimide

    FEBS Lett.

    (1988)
  • E. Holmberg et al.

    Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions

    Biochem. Biophys. Res. Commun.

    (1989)
  • H.C. Loughrey et al.

    Optimized procedures for the coupling of proteins to liposomes

    J. Immunol. Meth.

    (1990)
  • S. Zalipsky et al.

    Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine

    FEBS Lett.

    (1994)
  • S. Zalipsky et al.

    Preparation and applications of polyethylene glyol-polystyrene graft resin supports of solid phase peptide synthesis

    Reactive Polymers

    (1994)
  • T.M. Allen et al.

    A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells

    Biochim. Biophys. Acta

    (1995)
  • G. Blume et al.

    Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times

    Biochim. Biophys. Acta

    (1993)
  • S. Suzuki et al.

    Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol)

    Biochim. Biophys. Acta

    (1995)
  • P.G.M. Bloemen et al.

    Adhesion molecules: a new target for immunoliposome-mediated drug delivery

    FEBS Lett.

    (1995)
  • U.K. Nassander et al.

    Design of immunoliposomes directed against human ovarian carcinoma

    Biochim. Biophys. Acta

    (1995)
  • K. Maruyama et al.

    Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies

    Biochim. Biophys. Acta

    (1995)
  • D.L. Daleke et al.

    Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay

    Biochim. Biophys. Acta

    (1990)
  • B. Lundberg et al.

    Conjugation of apolipoprotein B with liposomes and targeting to cells in culture

    Biochim. Biophys. Acta

    (1993)
  • N.C. Phillips et al.

    Immunogenicity of immunoliposomes

    Immunol. Lett.

    (1991)
  • A. Sharma et al.

    Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumour model

    Cancer Res.

    (1993)
  • R.M. Straubinger et al.

    Novel taxol formulations: taxolcontaining liposomes

    Monographs Natl. Cancer Inst.

    (1993)
  • A.R. Scialli et al.

    Embryotoxicity of free and liposome encapsulated taxol in the chick

    Pharmacology

    (1995)
  • R. Perez-Soler et al.

    Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use

    J. Microencapsulation

    (1994)
  • A. Mori et al.

    In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes

    Cancer Chemother. Pharmacol.

    (1996)
  • E. Mayhew et al.

    Inhibition of tumour cell growth in vitro and in vivo by 1-β-D-arabinofuranosylcytosine entrapped within phospholipid vesicles

    Cancer Res.

    (1976)
  • S. Kim et al.

    Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy

    Cancer Treat. Rep.

    (1987)
  • F. Hong et al.

    Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine

    Cancer Res.

    (1989)
  • T.M. Allen et al.

    Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine

    Cancer Res.

    (1992)
  • A.A. Gabizon et al.

    Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times

    J. Natl. Cancer Inst.

    (1989)
  • A. Gabizon et al.

    Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

    Cancer Res.

    (1994)
  • B. Uziely et al.

    Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies

    J. Clin. Oncol.

    (1995)
  • F.-D. Goebel et al.

    Efficacy and safety of StealthR liposomal doxorubicin in AIDS-related Kaposi's sarcoma

    Br. J. Cancer

    (1996)
  • D.W. Northfelt et al.

    Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety inpatients with AIDS-related Kaposi's sarcoma

    J. Clin. Pharmacol.

    (1996)
  • J.W. Cowens et al.

    Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)

    Cancer Res.

    (1993)
  • Cited by (123)

    • Synthesis, characterization and evaluation of multi sensitive nanocarriers by using the layer by layer method

      2019, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      The size of these particular drug delivery systems plays a crucial role since permits to exploit the enhanced penetration and retention (EPR) effect [4], where the nanospheres extravasate into tumour tissue through discontinuous blood vessels and remain in that place due to impaired lymphatic drainage [5–9]. Additionally, introducing tumour targeting agents into these systems’ surface can also enhance their accumulation in cancer cells via active targeting [8,10–16]. This functionalization can strengthen the biodistribution of the carried drugs and invigorate the therapeutic index as well while minimizing side effects.

    • Molecular platforms for targeted drug delivery

      2019, International Review of Cell and Molecular Biology
      Citation Excerpt :

      Overall, this alternative system for the targeted controlled intracellular delivery of model macromolecules and small molecules loaded in the liposome-based on local microenvironmental activation showed promising results that now require in vivo validation. Subsequent studies investigated ligand-targeted liposomes as a strategy to increase interactions between liposomes and target cells and to enhance drug delivery (Allen and Moase, 1996). While non-targeted liposomal drug formulations display consistent therapeutic improvements in term of systemic toxicity when compared to free drug treatment (Safra et al., 2000), selective targeting of cells via ligand-directed liposomes will improve tumor drug accumulation and uptake, resulting in elevated anti-tumor effects (Park et al., 2002).

    View all citing articles on Scopus
    View full text